
Journal of International Oncology ›› 2025, Vol. 52 ›› Issue (10): 609-613.doi: 10.3760/cma.j.cn371439-20250312-00104
• Original Article • Previous Articles Next Articles
Dai Yujuan, Chen Xianying, Huang Wei, Chen Dachao(
)
Received:2025-03-12
Revised:2025-05-28
Online:2025-10-08
Published:2025-11-12
Contact:
Chen Dachao
E-mail:cdq13960179723@126.com
Supported by:Dai Yujuan, Chen Xianying, Huang Wei, Chen Dachao. Analysis of influencing factors and construction of a risk prediction model for early death in adult glioma[J]. Journal of International Oncology, 2025, 52(10): 609-613.
"
| 临床资料 | 死亡组(n=32) | 存活组(n=196) | χ2值 | P值 | 临床资料 | 死亡组(n=32) | 存活组(n=196) | χ2值 | P值 |
|---|---|---|---|---|---|---|---|---|---|
| 年龄(岁) | 入院KPS评分(分) | ||||||||
| <50 | 21 | 109 | 1.13 | 0.289 | ≤70 | 18 | 31 | 26.66 | <0.001 |
| ≥50 | 11 | 87 | >70 | 14 | 165 | ||||
| 性别 | 肿瘤最大径(cm) | ||||||||
| 男 | 21 | 116 | 0.48 | 0.490 | <3 | 18 | 112 | 0.01 | 0.925 |
| 女 | 11 | 80 | >3 | 14 | 84 | ||||
| 高血压 | 肿瘤分级 | ||||||||
| 有 | 8 | 25 | 2.42 | 0.120 | Ⅰ~Ⅱ | 11 | 156 | 28.70 | <0.001 |
| 无 | 24 | 171 | Ⅲ~Ⅳ | 21 | 40 | ||||
| 糖尿病 | MGMT启动子甲基化 | ||||||||
| 有 | 8 | 26 | 2.13 | 0.144 | 是 | 20 | 168 | 10.25 | 0.001 |
| 无 | 24 | 170 | 否 | 12 | 28 | ||||
| 肿瘤部位 | IDH野生型 | ||||||||
| 左侧 | 16 | 100 | 否 | 22 | 169 | 6.18 | 0.013 | ||
| 右侧 | 13 | 87 | 1.29 | 0.525 | 是 | 10 | 27 | ||
| 中线或双侧 | 3 | 9 | 肿瘤全切除 | ||||||
| 肿瘤累及范围 | 否 | 25 | 93 | 10.37 | 0.001 | ||||
| 单叶 | 18 | 123 | 0.49 | 0.482 | 是 | 7 | 103 | ||
| 多叶 | 14 | 73 | 化疗 | ||||||
| 脑疝 | 无 | 5 | 19 | 0.49 | 0.482 | ||||
| 无 | 18 | 173 | 20.74 | <0.001 | 有 | 27 | 177 | ||
| 有 | 14 | 23 | 放疗 | ||||||
| 神经功能受损 | 无 | 5 | 21 | 0.26 | 0.610 | ||||
| 无 | 24 | 171 | 2.42 | 0.120 | 有 | 27 | 175 | ||
| 有 | 8 | 25 |
"
| 因素 | β值 | SE值 | Wald χ2值 | OR值 | 95%CI | P值 |
|---|---|---|---|---|---|---|
| 脑疝(有/无) | 2.96 | 0.67 | 19.91 | 19.78 | 5.33~73.41 | <0.001 |
| 入院KPS评分(≤70分/>70分) | 2.98 | 0.65 | 21.27 | 19.64 | 5.54~69.59 | <0.001 |
| 肿瘤分级(Ⅲ~Ⅳ/Ⅰ~Ⅱ) | 2.24 | 0.58 | 14.96 | 9.40 | 3.02~29.27 | <0.001 |
| MGMT启动子甲基化(否/是) | 1.45 | 0.66 | 4.88 | 4.28 | 1.18~15.54 | 0.027 |
| IDH野生型(是/否) | 0.39 | 0.66 | 0.36 | 1.48 | 0.41~5.37 | 0.551 |
| 肿瘤全切除(否/是) | 2.25 | 0.64 | 12.42 | 9.50 | 2.72~33.23 | <0.001 |
| [1] | Yin J, Liu G, Zhang Y, et al. Gender differences in gliomas: from epidemiological trends to changes at the hormonal and molecular levels[J]. Cancer Lett, 2024, 598: 217114. DOI: 10.1016/j.canlet.2024.217114. |
| [2] |
Drexler R, Khatri R, Sauvigny T, et al. A prognostic neural epigenetic signature in high-grade glioma[J]. Nat Med, 2024, 30(6): 1622-1635. DOI: 10.1038/s41591-024-02969-w.
pmid: 38760585 |
| [3] | 国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35(3): 217-239. DOI: 10.3760/cma.j.issn.1001-2346.2019.03.001. |
| [4] | 陈雯琳, 王月坤, 刘千舒, 等. 2022年度我国脑胶质瘤领域研究进展[J]. 协和医学杂志, 2023, 14(5): 983-990. DOI: 10.12290/xhyxzz.2023-0321. |
| [5] | Huang F, Li S, Wang X, et al. Serum lipids concentration on prognosis of high-grade glioma[J]. Cancer Causes Control, 2023, 34(9): 801-811. DOI: 10.1007/s10552-023-01710-1. |
| [6] |
Zhang D, Li H, Jia W. Exploration of the prognostic value of the resection of adult brainstem high-grade glioma based on competing risk model, propensity score matching, and conditional survival rate[J]. Neurol Sci, 2023, 44(5): 1755-1764. DOI: 10.1007/s10072-022-06557-z.
pmid: 36604383 |
| [7] | Wu S, Wang C, Li N, et al. Analysis of prognostic factors and surgical management of elderly patients with low-grade gliomas[J]. World Neurosurg, 2023, 176: e20-e31. DOI: 10.1016/j.wneu.2023.02.099. |
| [8] |
Lin Y, Li H, Ge Q, et al. Establishment and validation of a prognostic prediction model for glioma based on key genes and clinical factors[J]. Transl Cancer Res, 2025, 14(1): 240-253. DOI: 10.21037/tcr-24-1035.
pmid: 39974385 |
| [9] | Hanif S, Yousaf I, Iqbal M, et al. Brain herniation and subsequent complications following partial resection of high-grade glioma: a case report[J]. Clin Case Rep, 2024, 12(1): e8407. DOI: 10.1002/ccr3.8407. |
| [10] | Lipková J, Menze B, Wiestler B, et al. Modelling glioma progression, mass effect and intracranial pressure in patient anatomy[J]. J R Soc Interface, 2022, 19(188): 20210922. DOI: 10.1098/rsif.2021.0922. |
| [11] | Pasqualetti F, Lombardi G, Gadducci G, et al. Brain stem glioma recurrence: exploring the therapeutic frontiers[J]. J Pers Med, 2024, 14(9): 899. DOI: 10.3390/jpm14090899. |
| [12] | Fuster-Garcia E, Thokle Hovden I, Fløgstad Svensson S, et al. Quantification of tissue compression identifies high-grade glioma patients with reduced survival[J]. Cancers (Basel), 2022, 14(7): 1725. DOI: 10.3390/cancers14071725. |
| [13] | Gunawan PY, Islam AA, July J, et al. Karnofsky performance scale and neurological assessment of neuro-oncology scale as early predictor in glioma[J]. Asian Pac J Cancer Prev, 2020, 21(11): 3387-3392. DOI: 10.31557/APJCP.2020.21.11.3387. |
| [14] | Hei B, Ouyang J, Gao Q, et al. Analysis of changes in KPS scores and imaging signs in deep brain gliomas by DWI combined with intraoperative ultrasound resection[J]. Altern Ther Health Med, 2024, 30(5): 110-117. DOI: 10.23736/S0390-5616.19.04735-0. |
| [15] | Shin I, Sim Y, Choi SH, et al. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas[J]. J Neurooncol, 2024, 168(2): 239-247. DOI: 10.1007/s11060-024-04656-9. |
| [16] | Kivioja T, Posti JP, Sipilä J, et al. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms[J]. Front Oncol, 2023, 13: 1305725. DOI: 10.3389/fonc.2023.1305725. |
| [17] | Decavèle M, Gatulle N, Weiss N, et al. One-year survival of patients with high-grade glioma discharged alive from the intensive care unit[J]. J Neurol, 2021, 268(2): 516-525. DOI: 10.1007/s00415-020-10191-0. |
| [18] | Wan Y, Li G, Deng J, et al. A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy[J]. Horm Cancer, 2023, 14(1): 202. DOI: 10.1007/s12672-023-00818-9. |
| [19] | Yu S, Wu J, Jing Y, et al. Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023)[J]. Front Oncol, 2025, 15: 1539937. DOI: 10.3389/fonc.2025.1539937. |
| [20] | Wetzel EA, Nohman AI, Hsieh AL, et al. A multi-center, clinical analysis of IDH-mutant gliomas, WHO grade 4: implications for prognosis and clinical trial design[J]. J Neurooncol, 2025, 171(2): 373-381. DOI: 10.1007/s11060-024-04852-7. |
| [21] | Zhang J, Qiu X, Feng J, et al. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas[J]. Chin Neurosurg J, 2024, 10(1): 24. DOI: 10.1186/s41016-024-00375-2. |
| [22] | Singh A, Singh A, Agrawal S, et al. Prognostic significance and clinicopathological correlations of epigenetic MGMT gene silencing in high grade diffuse gliomas[J]. Discoveries (Craiova), 2023, 11(3): e175. DOI: 10.15190/d.2023.14. |
| [23] | 朱一硕, 崔玉洁, 刘崎, 等. 脑胶质瘤患者术后早期复发危险因素分析及预测模型构建[J]. 国际肿瘤学杂志, 2022, 49(2): 79-83. DOI: 10.3760/cma.j.cn371439-20210121-00012. |
| [24] | Fan ZC, Zhao WJ, Jiao Y, et al. Risk factors and predictive nomogram for survival in elderly patients with brain glioma[J]. Curr Med Sci, 2024, 44(4): 759-770. DOI: 10.1007/s11596-024-2880-4. |
| [25] | 牛弘川, 梁剑峰. 脑胶质瘤预后因素分析及其列线图预测模型的建立[J]. 中华肿瘤防治杂志, 2023, 30(3): 140-146. DOI: 10.16073/j.cnki.cjcpt.2023.03.03. |
| [1] | Qiu Kexin, Li Mengzhen, Guo Haoran, Fan Mengsi, Yan Li. Prognostic analysis of different surgical approaches in elderly patients with advanced ovarian cancer [J]. Journal of International Oncology, 2025, 52(9): 576-582. |
| [2] | Liu Mei, Hu Yuchong, Li Fengtong, Chao Lemen, Liu Meng, Kang Linlin. Mechanism of action of SHCBP1 in malignant tumors and progress in clinical research [J]. Journal of International Oncology, 2025, 52(9): 583-586. |
| [3] | Lu Bing, Xiong Siyu, Jiang Wenhong, Yu Tingting. Progress in the study of fructose-bisphosphate aldolase A in lung cancer [J]. Journal of International Oncology, 2025, 52(4): 242-245. |
| [4] | Yang Shengjun, Ren Jiang, Yang Dan, Long Yu, Shang Qunxian. Expression levels and clinical significance of miR-4262,NRG1 in non-small cell lung cancer tissues [J]. Journal of International Oncology, 2025, 52(3): 129-135. |
| [5] | Wang Yi, Wang Qiangli, Zhang Jia, Yang Yijin, Wang Sheng. Relationship between the expression of SUCNR1 and YBX1 in tissues of patients with colorectal cancer liver metastases and their clinicopathological characteristics and prognosis [J]. Journal of International Oncology, 2025, 52(3): 152-157. |
| [6] | Han Tao, Jia Peipei, Lu Jing. Predictive value of iRhom1,iRhom2 and TNF-α levels for the prognosis of patients with cervical cancer [J]. Journal of International Oncology, 2025, 52(3): 158-162. |
| [7] | Li Zhiyuan, Jia Xiuhong. Research progress of copper death in tumor [J]. Journal of International Oncology, 2025, 52(3): 163-168. |
| [8] | Ye Yongying, Zou Yan, Chen Tianming, Wu Weili. Research progress of clock gene Period family in head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2025, 52(2): 113-118. |
| [9] | Chen Danlei, Deng Junjun, Li Miao. Progress of clinical application of circulating tumor cells in lung cancer [J]. Journal of International Oncology, 2025, 52(2): 119-123. |
| [10] | Ji Haitao, Wang Yanfeng, Liu Yongcheng, Hao Nan. Expression and clinical significance of DHCR7 in gastric cancer based on bioinformatics analysis [J]. Journal of International Oncology, 2025, 52(2): 94-100. |
| [11] | Lai Ruihe, Sheng Dandan, He Jian, Ding Chongyang, Geng Yuzhi. Prognostic value of 18F-FDG PET/CT metabolic parameters in small cell lung cancer [J]. Journal of International Oncology, 2025, 52(10): 614-620. |
| [12] | Yu Yang, Tang Shimin, Yang Lu, Li Na. Research progress in treatment strategies and prognostic factors for stage pT2-3N0M0 thoracic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2025, 52(1): 43-47. |
| [13] | Yuan Shengfang, Ren Jie, Lin Weijia, Ji Zexuan, Zhang Changhong, Wang Bu. Prognostic value of EGFR co-mutation status in patients with advanced lung adenocarcinoma [J]. Journal of International Oncology, 2024, 51(9): 556-562. |
| [14] | Guo Wei, Wang Donghui, Wang Zhenhua, Xue Zhaojun. Relationship between TFA-irAE after anti-PD-1 therapy and survival in advanced cancer patients [J]. Journal of International Oncology, 2024, 51(8): 481-486. |
| [15] | Ni Guoying, Huang Qian, Liang Hongxiang, Yang Zhiyong, Ding Yingli. Analysis of changes in serum miR-499 and miR-362 levels and their relationship with prognosis in advanced NSCLC patients [J]. Journal of International Oncology, 2024, 51(8): 487-492. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||